Sức Khỏe

Announcement of breakthrough solution in diabetes treatment in Vietnam

Diabetes mellitus (DM) is a chronic disease that is on the rise and is one of the top 10 leading causes of death from non-communicable diseases worldwide.

According to the World Diabetes Federation (IDF), by 2021, around the world, there are about 537 million people with diabetes, with more than 90% being type 2 diabetes. In Vietnam, the number of adults with diabetes according to IDF 2021 is about approx. 4.2 million, accounting for 6% of the population, of which more than 2 million are undiagnosed.

Although there have been many advances in the management of diabetes with many different classes of drugs in circulation, glycemic control has not improved much in the past 12 years. In Vietnam, the majority of patients with type 2 diabetes have poor glycemic control and poor metabolism. The percentage of patients who reached the target HbA1c <7.0% (<53 mmol/mol) was 36.1% and the mean HbA1c was 7.9 ± 1.8% (63 ± 19 mmol/mol).

Announcement of a breakthrough solution in the treatment of diabetes in Vietnam - photo 1

Dosage of iGlarLixi must be individualized based on clinical response and titrated based on the patient’s insulin needs.

Uncontrolled diabetes can lead to serious consequences with respect to quality of life, morbidity and mortality, as well as an increased risk of developing associated comorbidities. Therefore, timely intensification with insulin therapy to improve glycemic control is the right choice for many patients. However, with insulin therapy, patients also face challenges such as the potential for weight gain, the risk of hypoglycemia, or poor adherence.

New solutions in the treatment of type 2 diabetes in Vietnam

Recently, at the scientific conference “New solutions in the treatment of type 2 diabetes in Vietnam: A breakthrough step” organized by the General Medical Association with the sponsorship of Sanofi Vietnam company, in the form of: A fixed-ratio combination of basal insulin Glargine U100 and GLP-1 Lixisenatide receptor agonist, iGlarLixi, has been introduced to endocrinologists, diabetologists, general practitioners, and pharmacists across the country.

iGlarLixi is a pre-filled pen that combines two active ingredients with complementary mechanisms of action to improve glycemic control in patients with diabetes. The two active ingredients in iGlarLixi include: insulin glargine – a basal insulin analog (which mainly targets fasting blood sugar), and lixisenatide – a GLP-1 receptor agonist (which mainly targets postprandial blood sugar).

iGlarLixi has been demonstrated by clinical evidence to have the potential to provide positive outcomes such as helping to achieve early HbA1c control goals, without increasing the risk of hypoglycemia, reducing the risk of hypoglycemia, beneficial Benefits on weight, convenience to help patients adhere to treatment.

Who is the iGlarLixi solution suitable for?

Dosage of iGlarLixi must be individualized based on clinical response and titrated according to the patient’s insulin needs. iGlarLixi is administered with only 1 injection within 1 hour before the most convenient meal of the day. According to experts, the beneficiaries of the iGlarLixi fixed-ratio combination are patients with HbA1c > 9%, obese patients, people at high risk of hypoglycemia, postprandial hyperglycemia and have a history of gastrointestinal side effects. In particular, the elderly, especially those who are weak or live alone, cannot apply the carbohydrate calculation regime in the meal…

Besides, the convenience of 1 injection/day is also very important when helping patients simplify the treatment regimen. Associate Professor Dr. Nguyen Thi Bich Dao, Vice President of the Vietnam Society of Endocrinology & Diabetes, said: “Many studies have shown that early drug combination helps to better control blood sugar and reduce the risk of complications. evidence for the patient. iGlalixi is a solution to help overcome the situation of complicated treatment regimens, and many insulin injections in a day, improving blood sugar control better.”

Associate Professor Dr. Nguyen Khoa Dieu Van – Vice President of the Vietnam Association of Endocrinology & Diabetes said: “This is a solution that can support endocrinologists in individualizing treatment to achieve their goals. control blood sugar, help patients adhere to treatment and minimize complications. With the advantage of being suitable for patients who do not respond to pills, or do not meet their treatment goals when using only insulin glargine, this solution can help patients achieve HbA1C results sooner and better, with less risk. lower blood sugar, less weight gain”.

In addition to taking medication, people with diabetes also need to follow a scientific diet and exercise to create a firm “tripod” posture, helping diabetics control blood sugar better. .

You are reading the article Announcement of breakthrough solution in diabetes treatment in Vietnam

at Blogtuan.info – Source: thanhnien.vn – Read the original article here

Back to top button